Methods of treating cancer having an active Wnt/β-catenin pathway
AssigneeDana-Farber Cancer Institute, Inc.
InventorsWilliam C. Hahn, Joseph Rosenbluh
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of treating a subject having a Wnt/beta-catenin active cancer by administering to said subject a compound that inhibits the expression or activity of YES1, BIRC5 or BCL2L1, a compound that inhibits YAP1-beta-catenin complex formation, a compound that inhibits YAP1-beta-catenin complex binding to DNA, a compound that inhibits YAP1-beta-catenin-TBX5 complex formation, or any combination thereof. The compound can be, for example, a nucleic acid, a peptide, an antibody or a small molecule. Methods of screening for therapeutic targets for treating cancer are included.
Claims14
A method of reducing YES1 activity thereby treating a Wnt/β-catenin active cancer in a human subject in need thereof, the method consisting of administering to the human subject a therapeutic amount of dasatinib effective to reduce YES1 activity, wherein the Wnt/β-catenin active cancer is colon cancer, breast cancer, lung cancer, leukemia, prostate cancer, skin cancer, liver cancer, ovarian cancer, brain cancer, or parathyroid cancer.
A method of reducing YES1 activity thereby treating a Wnt/β-catenin active cancer in a human subject in need thereof, the method consisting of administering to the human subject a therapeutic amount of dasatinib effective to reduce YES1 activity, wherein a level of β-catenin in the Wnt/β-catenin active cancer is unaffected upon administering the YES1 inhibitor.
Dependencies are inferred from the claim text.